Literature DB >> 19948834

Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1.

Sheetij Dutta1, Lisa S Dlugosz, Joshua W Clayton, Christopher D Pool, J David Haynes, Robert A Gasser, Adrian H Batchelor.   

Abstract

Antibodies against apical membrane antigen 1 (AMA1) inhibit invasion of Plasmodium merozoites into red cells, and a large number of single nucleotide polymorphisms on AMA1 allow the parasite to escape inhibitory antibodies. The availability of a crystal structure makes it possible to test protein engineering strategies to develop a monovalent broadly reactive vaccine. Previously, we showed that a linear stretch of polymorphic residues (amino acids 187 to 207), localized within the C1 cluster on domain 1, conferred the highest level of escape from inhibitory antibodies, and these were termed antigenic escape residues (AER). Here we test the hypothesis that immunodampening the C1 AER will divert the immune system toward more conserved regions. We substituted seven C1 AER of the FVO strain Plasmodium falciparum AMA1 with alanine residues (ALA). The resulting ALA protein was less immunogenic than the native protein in rabbits. Anti-ALA antibodies contained a higher proportion of cross-reactive domain 2 and domain 3 antibodies and had higher avidity than anti-FVO. No overall enhancement of cross-reactive inhibitory activity was observed when anti-FVO and anti-ALA sera were compared for their ability to inhibit invasion. Alanine mutations at the C1 AER had shifted the immune response toward cross-strain-reactive epitopes that were noninhibitory, refuting the hypothesis but confirming the importance of the C1 cluster as an inhibitory epitope. We further demonstrate that naturally occurring polymorphisms that fall within the C1 cluster can predict escape from cross-strain invasion inhibition, reinforcing the importance of the C1 cluster genotype for antigenic categorization and allelic shift analyses in future phase 2b trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948834      PMCID: PMC2812209          DOI: 10.1128/IAI.00866-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design.

Authors:  Junhui Duan; Jianbing Mu; Mahamadou Ali Thera; Deirdre Joy; Sergei L Kosakovsky Pond; David Diemert; Carole Long; Hong Zhou; Kazutoyo Miura; Amed Ouattara; Amagana Dolo; Ogobara Doumbo; Xin-Zhuan Su; Louis Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-30       Impact factor: 11.205

2.  Specificity of the protective antibody response to apical membrane antigen 1.

Authors:  A N Hodder; P E Crewther; R F Anders
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species.

Authors:  T Triglia; J Healer; S R Caruana; A N Hodder; R F Anders; B S Crabb; A F Cowman
Journal:  Mol Microbiol       Date:  2000-11       Impact factor: 3.501

4.  Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli.

Authors:  Sheetij Dutta; P V Lalitha; Lisa A Ware; Arnoldo Barbosa; J Kathleen Moch; Meredith A Vassell; Bader B Fileta; Svetlana Kitov; Nelly Kolodny; D Gray Heppner; J David Haynes; David E Lanar
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Authors:  Sheetij Dutta; JoAnn S Sullivan; Katharine K Grady; J David Haynes; Jack Komisar; Adrian H Batchelor; Lorraine Soisson; Carter L Diggs; D Gray Heppner; David E Lanar; William E Collins; John W Barnwell
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

6.  A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali.

Authors:  Issaka Sagara; Alassane Dicko; Ruth D Ellis; Michael P Fay; Sory I Diawara; Mahamadoun H Assadou; Mahamadou S Sissoko; Mamady Kone; Abdoulbaki I Diallo; Renion Saye; Merepen A Guindo; Ousmane Kante; Mohamed B Niambele; Kazutoyo Miura; Gregory E D Mullen; Mark Pierce; Laura B Martin; Amagana Dolo; Dapa A Diallo; Ogobara K Doumbo; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

7.  Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

Authors:  Shannon L Takala; Drissa Coulibaly; Mahamadou A Thera; Adrian H Batchelor; Michael P Cummings; Ananias A Escalante; Amed Ouattara; Karim Traoré; Amadou Niangaly; Abdoulaye A Djimdé; Ogobara K Doumbo; Christopher V Plowe
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

8.  An inhibitory antibody blocks interactions between components of the malarial invasion machinery.

Authors:  Christine R Collins; Chrislaine Withers-Martinez; Fiona Hackett; Michael J Blackman
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

9.  Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Authors:  Michele D Spring; James F Cummings; Christian F Ockenhouse; Sheetij Dutta; Randall Reidler; Evelina Angov; Elke Bergmann-Leitner; V Ann Stewart; Stacey Bittner; Laure Juompan; Mark G Kortepeter; Robin Nielsen; Urszula Krzych; Ev Tierney; Lisa A Ware; Megan Dowler; Cornelus C Hermsen; Robert W Sauerwein; Sake J de Vlas; Opokua Ofori-Anyinam; David E Lanar; Jack L Williams; Kent E Kester; Kathryn Tucker; Meng Shi; Elissa Malkin; Carole Long; Carter L Diggs; Lorraine Soisson; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; D Gray Heppner
Journal:  PLoS One       Date:  2009-04-23       Impact factor: 3.240

10.  Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Dapa A Diallo; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Alassane Dicko; Issaka Sagara; Mahamadou S Sissoko; Mounirou Baby; Mady Sissoko; Issa Diarra; Amadou Niangaly; Amagana Dolo; Modibo Daou; Sory I Diawara; D Gray Heppner; V Ann Stewart; Evelina Angov; Elke S Bergmann-Leitner; David E Lanar; Sheetij Dutta; Lorraine Soisson; Carter L Diggs; Amanda Leach; Alex Owusu; Marie-Claude Dubois; Joe Cohen; Jason N Nixon; Aric Gregson; Shannon L Takala; Kirsten E Lyke; Christopher V Plowe
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

View more
  18 in total

Review 1.  Vaccines for malaria: how close are we?

Authors:  Mahamadou A Thera; Christopher V Plowe
Journal:  Annu Rev Med       Date:  2011-11-10       Impact factor: 13.739

Review 2.  Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Authors:  Ruth D Ellis; Issaka Sagara; Ogobara Doumbo; Yimin Wu
Journal:  Hum Vaccin       Date:  2010-08

3.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

4.  3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria.

Authors:  Manuel A Patarroyo; Adriana Bermúdez; Carolina López; Gloria Yepes; Manuel E Patarroyo
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

5.  Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications.

Authors:  Amed Ouattara; Shannon Takala-Harrison; Mahamadou A Thera; Drissa Coulibaly; Amadou Niangaly; Renion Saye; Youssouf Tolo; Sheetij Dutta; D Gray Heppner; Lorraine Soisson; Carter L Diggs; Johan Vekemans; Joe Cohen; William C Blackwelder; Tina Dube; Matthew B Laurens; Ogobara K Doumbo; Christopher V Plowe
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

6.  A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants.

Authors:  Leyla Y Bustamante; S Josefin Bartholdson; Cecile Crosnier; Marta G Campos; Madushi Wanaguru; Chea Nguon; Dominic P Kwiatkowski; Gavin J Wright; Julian C Rayner
Journal:  Vaccine       Date:  2012-11-10       Impact factor: 3.641

7.  Genetic mapping identifies novel highly protective antigens for an apicomplexan parasite.

Authors:  Damer P Blake; Karen J Billington; Susan L Copestake; Richard D Oakes; Michael A Quail; Kiew-Lian Wan; Martin W Shirley; Adrian L Smith
Journal:  PLoS Pathog       Date:  2011-02-10       Impact factor: 6.823

8.  Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.

Authors:  Erin Crossey; Kathryn Frietze; David L Narum; David S Peabody; Bryce Chackerian
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

Authors:  Sheetij Dutta; Lisa S Dlugosz; Damien R Drew; Xiaopeng Ge; Xiopeng Ge; Diouf Ababacar; Yazmin I Rovira; J Kathleen Moch; Meng Shi; Carole A Long; Michael Foley; James G Beeson; Robin F Anders; Kazutoyo Miura; J David Haynes; Adrian H Batchelor
Journal:  PLoS Pathog       Date:  2013-12-26       Impact factor: 6.823

10.  Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.

Authors:  Damien R Drew; Anthony N Hodder; Danny W Wilson; Michael Foley; Ivo Mueller; Peter M Siba; Arlene E Dent; Alan F Cowman; James G Beeson
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.